PNC Financial Services Group
HRTX icon

PNC Financial Services Group’s Heron Therapeutics HRTX Stock Holding History

PNC Financial Services Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-173
Closed -$358 – 5142
2025
Q2 		$358 Hold
173
– – ﹤0.01% 4727
2025
Q1 		$381 Buy
173
+56
+48% +$109 ﹤0.01% 4688
2024
Q4 		$179 Hold
117
– – ﹤0.01% 4658
2024
Q3 		$233 Hold
117
– – ﹤0.01% 4665
2024
Q2 		$410 Hold
117
– – ﹤0.01% 4556
2024
Q1 		$324 Sell
117
-1,500
-93% -$3.77K ﹤0.01% 4543
2023
Q4 		$2.75K Sell
1,617
-91
-5% -$100 ﹤0.01% 4114
2023
Q3 		$1.76K Hold
1,708
– – ﹤0.01% 4277
2023
Q2 		$1.98K Hold
1,708
– – ﹤0.01% 4385
2023
Q1 		$2.58K Hold
1,708
– – ﹤0.01% 4242
2022
Q4 		$4.27K Sell
1,708
-400
-19% -$1.29K ﹤0.01% 4045
2022
Q3 		$8K Hold
2,108
– – ﹤0.01% 3839
2022
Q2 		$5K Sell
2,108
-293
-12% -$1.18K ﹤0.01% 3995
2022
Q1 		$15K Buy
2,401
+693
+41% +$5.07K ﹤0.01% 3702
2021
Q4 		$16K Hold
1,708
– – ﹤0.01% 3626
2021
Q3 		$18K Sell
1,708
-3,292
-66% -$40.1K ﹤0.01% 3552
2021
Q2 		$78K Buy
5,000
+1,189
+31% +$18.9K ﹤0.01% 2801
2021
Q1 		$62K Buy
3,811
+91
+2% +$1.62K ﹤0.01% 2854
2020
Q4 		$79K Sell
3,720
-689
-16% -$12K ﹤0.01% 2634
2020
Q3 		$65K Buy
4,409
+273
+7% +$4.26K ﹤0.01% 2574
2020
Q2 		$61K Buy
4,136
+1,438
+53% +$23.6K ﹤0.01% 2649
2020
Q1 		$32K Buy
2,698
+2,064
+326% +$38.8K ﹤0.01% 2876
2019
Q4 		$14K Sell
634
-192
-23% -$4.25K ﹤0.01% 3423
2019
Q3 		$15K Buy
826
+184
+29% +$3.39K ﹤0.01% 3438
2019
Q2 		$12K Sell
642
-73,106
-99% -$1.46M ﹤0.01% 3514
2019
Q1 		$1.8M Buy
73,748
+26,867
+57% +$703K ﹤0.01% 1074
2018
Q4 		$1.22M Sell
46,881
-2,331
-5% -$64.1K ﹤0.01% 1176
2018
Q3 		$1.56M Buy
49,212
+419
+0.9% +$15.6K ﹤0.01% 1160
2018
Q2 		$1.9M Buy
+48,793
New +$1.55M ﹤0.01% 1069
2017
Q4 		– Sell
-1,500
Closed -$24K – 4183
2017
Q3 		$24K Hold
1,500
– – ﹤0.01% 3297
2017
Q2 		$21K Hold
1,500
– – ﹤0.01% 3316
2017
Q1 		$23K Hold
1,500
– – ﹤0.01% 3238
2016
Q4 		$20K Buy
1,500
+723
+93% +$11.3K ﹤0.01% 3234
2016
Q3 		$13K Hold
777
– – ﹤0.01% 3397
2016
Q2 		$14K Sell
777
-2,000
-72% -$39K ﹤0.01% 3400
2016
Q1 		$53K Sell
2,777
-1,200
-30% -$23.7K ﹤0.01% 2798
2015
Q4 		$106K Buy
3,977
+1,920
+93% +$51.3K ﹤0.01% 2418
2015
Q3 		$51K Buy
2,057
+80
+4% +$2.67K ﹤0.01% 2860
2015
Q2 		$62K Buy
+1,977
New +$37.2K ﹤0.01% 2899

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PNC Financial Services Group's HRTX Position: Q3 2025 in Review

PNC Financial Services Group sold out of Heron Therapeutics (HRTX) in Q3 2025, closing a stake of 173 shares — an estimated $358 sold.

PNC Financial Services Group first reported a position in HRTX in Q2 2015 and held it in 39 quarters. The position peaked at $1.9M in Q2 2018. 172 funds tracked by Wall St. Rank hold HRTX as of Q3 2025.

  • PNC Financial Services Group reported no remaining Heron Therapeutics position as of Q3 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 173 Heron Therapeutics shares in Q3 2025, an estimated $358.
  • PNC Financial Services Group first reported a position in Heron Therapeutics in Q2 2015 and held it in 39 quarters.
  • PNC Financial Services Group's Heron Therapeutics position peaked at $1.9M in Q2 2018.
  • 172 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2025.

Based on PNC Financial Services Group's 13F filing for Q3 2025, filed 7 Nov 2025.